COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science, Inc. (OTCBB:CBIS) a pioneering US biotech company developing pharmaceutical cannabis products, as part of our public education mission, is pleased to release a growing list of peer-reviewed, cannabis and cancer references from researchers around the world.
President of Cannabis Science, Dr. Robert Melamede said, “This list of peer-reviewed manuscripts, provides support for the anecdotal observations of an increasing number of patients claiming successful cancer treatment using medical cannabis extracts. The scientific documentation of the anti-cancer and anti-metastatic properties of cannabinoids is a driving force behind behind our long-term goal, to make high quality, effective, reliable and safe cannabis extracts available to the public beyond the borders of current medical marijuana states. We continue to receive a constant flow of patent enquiries as to what treatment options are available. Currently, two Cannabis Science extracts are available in one Colorado-licensed medical marijuana dispensary (Cannabis Therapeutics). One product is grown hydroponically, whereas the second preparation is grown in soil.
Below are selected references that show the breadth and depth of the anti-cancer activities possessed by cannabinoids.
Peer Reviewed Cannabis and Cancer References resulting from a PubMed search (NIH database of biomedical research).
1. Proto, M. C. et al. Interaction of endocannabinoid system and steroid Hormones in the control of colon cancer cell growth. J Cell Physiol 227, 250-258 (2012).
2. Hermanson, D. J. & Marnett, L. J. Cannabinoids, endocannabinoids, and cancer. Cancer Metastasis Rev (2011).
3. Bowles, D. W., O’Bryant, C. L., Camidge, D. R. & Jimeno, A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol (2011).
4. Diaz-Laviada, I. The endocannabinoid system in prostate cancer. Nat Rev Urol 8, 553-561 (2011).
5. Scuderi, M. R. et al. The antimitogenic effect of the cannabinoid receptor agonist WIN55212-2 on human melanoma cells is mediated by the membrane lipid raft. Cancer Lett 310, 240-249 (2011).
6. Malfitano A. M. et al. Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15, 297-308 (2011).
7. Shrivastava, A., Kuzontkoski, P. M., Groopman, J. E. & Prasad, A. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10, 1161-1172 (2011).
8. Vara, D. et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18, 1099-1111 (2011).
9. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids attenuate cancer pain and proliferation in a mouse model. Neurosci Lett 488, 247-251 (2011).
10. Guindon, J. & Hohmann, A. G. The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163, 1447-1463 (2011).
*** The list in its entirety can be viewed via the www.cannabisscience.com website
Cannabis Science, Inc. is at the forefront of pharmaceutical grade medical marijuana research and development. The first formulations will address the needs of patients choosing to use concentrated cannabis extracts to treat their ailments. Eventually, all Americans will have access to a safe and effective FDA approved medicine regardless of which state they live in. To maintain that marijuana is a dangerous, addictive drug with no medical value is scientifically absurd. Cannabis medicines, with no effective lethal dose, are far safer than aspirin, acetaminophen, and most other OTC drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements; This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science Inc.
Investor Relations Management
Dr. Robert J. Melamede Ph.D.
President & CEO
KEYWORDS: United States North America California Colorado
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical Other Health Communications Research Other Science Publishing Other Communications Science